[go: up one dir, main page]

AR037937A1 - Composiciones farmaceuticas de agonista parcial de 5ht4 - Google Patents

Composiciones farmaceuticas de agonista parcial de 5ht4

Info

Publication number
AR037937A1
AR037937A1 ARP020105024A ARP020105024A AR037937A1 AR 037937 A1 AR037937 A1 AR 037937A1 AR P020105024 A ARP020105024 A AR P020105024A AR P020105024 A ARP020105024 A AR P020105024A AR 037937 A1 AR037937 A1 AR 037937A1
Authority
AR
Argentina
Prior art keywords
partial agonist
pharmaceutical compositions
percent
weight
amount
Prior art date
Application number
ARP020105024A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR037937A1 publication Critical patent/AR037937A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición farmacéutica sólida para administración oral, la cual comprende un agonista parcial de 5-HT4 en particulas tegaserod en forma de base o sal, en una cantidad de hasta el 10 por ciento en peso, un agente de volumen en una cantidad del 70 al 90 por ciento en peso, un desintegrante en una cantidad menor al 15 por ciento en peso, un abrillantador, y un lubricante.
ARP020105024A 2001-12-21 2002-12-19 Composiciones farmaceuticas de agonista parcial de 5ht4 AR037937A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01403339A EP1321142A1 (en) 2001-12-21 2001-12-21 Solid pharmaceutical composition for oral administration of Tegaserod

Publications (1)

Publication Number Publication Date
AR037937A1 true AR037937A1 (es) 2004-12-22

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020105024A AR037937A1 (es) 2001-12-21 2002-12-19 Composiciones farmaceuticas de agonista parcial de 5ht4

Country Status (31)

Country Link
US (2) US20050106236A1 (es)
EP (2) EP1321142A1 (es)
JP (1) JP4718776B2 (es)
KR (1) KR100980144B1 (es)
CN (1) CN100464749C (es)
AR (1) AR037937A1 (es)
AT (1) ATE320807T1 (es)
AU (1) AU2002361198B2 (es)
BR (1) BR0215148A (es)
CA (1) CA2470668C (es)
CO (1) CO5640102A2 (es)
CY (1) CY1105559T1 (es)
DE (1) DE60210139T2 (es)
DK (1) DK1458377T3 (es)
EC (1) ECSP105163A (es)
EG (1) EG24194A (es)
ES (1) ES2258171T3 (es)
HU (1) HU226589B1 (es)
IL (2) IL162451A0 (es)
MX (1) MXPA04006157A (es)
MY (1) MY139546A (es)
NO (1) NO20042779L (es)
NZ (1) NZ533585A (es)
PE (1) PE20030872A1 (es)
PL (1) PL369509A1 (es)
PT (1) PT1458377E (es)
RU (1) RU2322978C2 (es)
SI (1) SI1458377T1 (es)
TW (1) TWI260221B (es)
WO (1) WO2003053432A1 (es)
ZA (1) ZA200404467B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL200132B1 (pl) * 1998-08-21 2008-12-31 Novartis Ag Zastosowanie 3-(5-metoksy-1H-indol-3-ilometyleno)-N-pentylokarbazyimidoamidu
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004069165A2 (en) 2003-01-28 2004-08-19 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2003222439A1 (en) * 2003-03-25 2004-10-18 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
WO2004104577A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
MY137386A (en) * 2003-07-24 2009-01-30 Novartis Ag Stable modifications of tegaserod hydrogen maleate
ES2737348T3 (es) 2003-09-12 2020-01-13 Amgen Inc Formulación de disolución rápida que comprende cinacalcet HCl
WO2005058819A2 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
SI2384318T1 (en) 2008-12-31 2018-03-30 Ardelyx, Inc. MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
RU2015107019A (ru) 2012-08-21 2016-10-10 Эрделикс Инк. Соединения и способы для ингибирования nhe-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой и заболеваний желудочно-кишечного тракта
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
MX382203B (es) 2013-04-12 2025-03-11 Ardelyx Inc Compuestos de union a nhe3 (intercambiador de sodio-hidrogeno 3) y metodos para inhibir transporte de fosfato.
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
EA036204B1 (ru) * 2015-10-16 2020-10-14 Нобел Илач Санайи Ве Тиджарет А.Ш. Фармацевтические композиции нилотиниба гидрохлорида
UA126283C2 (uk) 2017-01-09 2022-09-14 Арделікс, Інк. Сполуки, придатні для лікування розладів шлунково-кишкового тракту
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Ｎｈｅ媒介性アンチポートの阻害薬

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
PL200132B1 (pl) * 1998-08-21 2008-12-31 Novartis Ag Zastosowanie 3-(5-metoksy-1H-indol-3-ilometyleno)-N-pentylokarbazyimidoamidu
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
WO2001008687A1 (en) * 1999-08-03 2001-02-08 Lilly Icos Llc Beta-carboline pharmaceutical compositions

Also Published As

Publication number Publication date
KR20040066922A (ko) 2004-07-27
AU2002361198B2 (en) 2006-06-08
CN100464749C (zh) 2009-03-04
JP2005516946A (ja) 2005-06-09
SI1458377T1 (sl) 2006-08-31
US20090104263A1 (en) 2009-04-23
CA2470668A1 (en) 2003-07-03
ECSP105163A (es) 2010-07-30
EP1458377B1 (en) 2006-03-22
CY1105559T1 (el) 2010-07-28
PE20030872A1 (es) 2003-11-24
DE60210139D1 (de) 2006-05-11
CO5640102A2 (es) 2006-05-31
RU2322978C2 (ru) 2008-04-27
ATE320807T1 (de) 2006-04-15
EG24194A (en) 2008-10-14
EP1458377A1 (en) 2004-09-22
HUP0402492A3 (en) 2008-04-28
MXPA04006157A (es) 2004-10-27
ES2258171T3 (es) 2006-08-16
ZA200404467B (en) 2006-05-31
IL162451A (en) 2009-02-11
PT1458377E (pt) 2006-07-31
WO2003053432A1 (en) 2003-07-03
TW200410684A (en) 2004-07-01
AU2002361198A1 (en) 2003-07-09
JP4718776B2 (ja) 2011-07-06
BR0215148A (pt) 2004-10-19
NZ533585A (en) 2006-04-28
NO20042779L (no) 2004-09-17
MY139546A (en) 2009-10-30
HU226589B1 (en) 2009-04-28
IL162451A0 (en) 2005-11-20
PL369509A1 (en) 2005-04-18
EP1321142A1 (en) 2003-06-25
HUP0402492A2 (hu) 2005-07-28
DK1458377T3 (da) 2006-06-12
RU2004122631A (ru) 2005-08-10
US20050106236A1 (en) 2005-05-19
KR100980144B1 (ko) 2010-09-03
CN1606438A (zh) 2005-04-13
DE60210139T2 (de) 2006-08-17
TWI260221B (en) 2006-08-21
CA2470668C (en) 2011-07-05

Similar Documents

Publication Publication Date Title
ECSP105163A (es) Composiciones farmaceuticas de agonista parcial de 5ht4
WO2004000197A3 (en) Quick dissolve compositions and tablets based thereon
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
ECSP088239A (es) Composición de liberación de fármaco sostenida
TW200517106A (en) Sustained release pharmaceutical compositions
MXPA05005709A (es) Composiciones farmaceuticas que comprenden un compuesto farmacologico basico respectivamente acido, un agente tensioactivo y un acido hidrosoluble fisiologicamente tolerable respectivamente base.
AR033711A1 (es) Composiciones farmaceuticas
CO5390076A1 (es) Composiciones farmaceuticas
BRPI0619572B8 (pt) método para a preparação de um carbonato de cálcio revestido com película, método para a preparação de tablete farmacêutico ou nutricional compreendendo um carbonato de cálcio revestido com película, carbonato de cálcio revestido com película e composição farmacêutica ou nutricional
PE20050755A1 (es) Composicion farmaceutica que comprende multiparticulas de acido micofenolico o micofenolato de sodio y combinacion de la composicion con rapamicina
ATE519486T1 (de) Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem acetylcholinesterase-hemmer
BR0316170A (pt) Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer
EA200400357A1 (ru) Дезинтегрирующиеся в ротовой полости композиции валдекоксиба
TR200401793T4 (tr) Perindopril tuzu ve bunu içeren farmasötik bileşimler.
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
BR0008509A (pt) Composição farmacêutica oral estabilizada contendo iodeto e iodato e método
BRPI0413676A (pt) composto, e, composição farmacêutica
CO6150126A2 (es) Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina
PH12022550937A1 (en) Pharmaceutical composition comprising selexipag
CO5650219A2 (es) Pelicula antiplaca consumible refrescante del aliento
CL2008003231A1 (es) Compuestos derivados de 1,3-dihidro-5-isobenzofurancarbonitrilo sustituido, inhibidores selectivos de la recaptacion de serotonina; composicion farmaceutica; procedimiento de preparacion; utiles en el tratamiento y/o prevencion de la eyaculacion prematura.
ES2422730T3 (es) Sales de tiotropio, procedimiento para su preparación, así como formulaciones de medicamentos que las contienen
BR0318646A (pt) composição de branqueamento de dentes oral sólida
AR024232A1 (es) Bromhidrato de eletriptan monohidratado, composicion farmaceutica, su uso en la preparacion de medicamentos y procedimiento para su preparacion
ES2422729T3 (es) Sales de tiotropio, procedimiento para su preparación y formulaciones de medicamentos que las contienen

Legal Events

Date Code Title Description
FC Refusal